Editing Genes...Preclinical Promise

. . . Editing Genes - It seems that the some of the human genome's "errors" may soon be able to be corrected with new gene editing technology. Sangamo BioSciences (Nasdaq: SGMO) has announced the results of a study demonstrating that its zinc finger DNA-binding protein technology achieved "highly efficient, permanent correction of a disease-causing gene in primary human cells." ZFN Technology facilitated the modification of a DNA sequence at the site of a mutation in the gene. The study also indicated that gene correction was permanent.

. . . Preclinical Promise - Pre-clinical data demonstrated that Tarvacin(TM) from Peregrine Pharmaceuticals (Nasdaq: PPHM), and related Anti-Phospholipid Therapy agents, have anti-viral therapy which may have far reaching implications for the treatment of infectious disease. According to Dr. Philip Thorpe, professor of pharmacology at UT Southwestern, "since Tarvacin(TM) targets a basic, universal property of enveloped viruses that is host-derived and independent of the viral genome, it may be effective against a broad spectrum of enveloped viruses."

From: www.InvestingIN.com/biotech